The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Implementing TMB measurement in clinical practice: considerations on assay requirements
Open accessAbstract
Clinical evidence demonstrates that treatment with immune checkpoint inhibitor immunotherapy agents can have considerable benefit across multiple tumours. However, there is a need for the development of predictive biomarkers that identify patients who are most likely to respond to immunotherapy. Comprehensive characterisation of tumours using genomic, transcriptomic, and proteomic approaches continues to lead the way in advancing precision medicine. Genetic correlates of response to therapy have been known for some time, but recent clinical evidence has strengthened the significance of high tumour mutational burden (TMB) as a biomarker of response and hence a rational target for immunotherapy. Concordantly, immune checkpoint inhibitors have changed clinical practice for lung cancer and melanoma, which are tumour types with some of the highest mutational burdens. TMB is an implementable approach for molecular biology and/or pathology laboratories that provides a quantitative measure of the total number of mutations in tumour tissue of patients and can be assessed by whole genome, whole exome, or large targeted gene panel sequencing of biopsied material. Currently, TMB assessment is not standardised across research and clinical studies. As a biomarker that affects treatment decisions, it is essential to unify TMB assessment approaches to allow for reliable, comparable results across studies. When implementing TMB measurement assays, it is important to consider factors that may impact the method workflow, the results of the assay, and the interpretation of the data. Such factors include biopsy sample type, sample quality and quantity, genome coverage, sequencing platform, bioinformatic pipeline, and the definitions of the final threshold that determines high TMB. This review outlines the factors for adoption of TMB measurement into clinical practice, providing an understanding of TMB assay considerations throughout the sample journey, and suggests principles to effectively implement TMB assays in a clinical setting to aid and optimise treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 15×
“FoundationOne CDx and MSK-IMPACT assays cover ~0.8 Mb over 324 genes and ~1.5 Mb over 468 genes, respectively.14 62 Some evidence suggests that smaller gene panels may be sufficient for TMB assessment,63 but other evidence indicates that they may only be sufficient to detect hypermutated and ultramutated tumours and t…”
BackgroundMethodInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Three gene panel tests (FoundationOne, FoundationOne CDx, and MSK-IMPACT) have documented good concordance with TMB assessment by WES using both empirical and in silico approaches.(15) 52–55 Therefore, gene panels potentially provide an effective approach for TMB estimation in clinical practice.”
MethodTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“87 88 To date, the TMB threshold of ≥10 mut/Mb, measured by FoundationOne CDx (equivalent to ~200 mutations by WES) in first-line patients with non-small cell lung cancer (NSCLC), is the only cut-off established for enhanced response to immunotherapy in one trial and clinically validated in a separate study using a pr…”
MethodGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401 · cited 1×
“29–33 The mutational landscape can also vary across the tumour and evolve during tumour development or following treatment.(22) 34 Tumours with high TMB may exhibit specific genetic alterations associated with clinical benefit to immunotherapy.”
BackgroundTracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Targeted capture and massively parallel sequencing of 12 human exomes
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E. E., et al. (2009) · Nature · doi:10.1038/nature08250 · Cited by 2,030
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0013 · Cited by 1,784
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Landscape of Microsatellite Instability Across 39 Cancer Types
Bonneville, R., Krook, M. A., Kautto, E. A., Miya, J., Wing, M. R., Chen, H.-Z., Reeser, J. W., Yu, L., & Roychowdhury, S. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00073 · Cited by 1,476
Sequencing depth and coverage: key considerations in genomic analyses
Sims, D., Sudbery, I., Ilott, N. E., Heger, A., & Ponting, C. P. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3642 · Cited by 1,393
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids
Srinivasan, M., Sedmak, D., & Jewell, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64472-0 · Cited by 1,318
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249 · cited 6×
“FoundationOne CDx and MSK-IMPACT assays cover ~0.8 Mb over 324 genes and ~1.5 Mb over 468 genes, respectively.14 62 Some evidence suggests that smaller gene panels may be sufficient for TMB assessment,63 but other evidence indicates that they may only be sufficient to detect hypermutated and ultramutated tumours and t…”
BackgroundInfluentialGandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0134-3 · Cited by 1,157
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.018 · Cited by 1,095 · cited 8×
“FoundationOne CDx and MSK-IMPACT assays cover ~0.8 Mb over 324 genes and ~1.5 Mb over 468 genes, respectively.14 62 Some evidence suggests that smaller gene panels may be sufficient for TMB assessment,63 but other evidence indicates that they may only be sufficient to detect hypermutated and ultramutated tumours and t…”
BackgroundInfluentialMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.8671 · Cited by 959
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Roh, W., Chen, P.-L., Reuben, A., Spencer, C. N., Prieto, P. A., Miller, J. P., Gopalakrishnan, V., Wang, F., Cooper, Z. A., Reddy, S. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3560 · Cited by 859
Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857
Comprehensive Analysis of Hypermutation in Human Cancer
Campbell, B. B., Light, N., Fabrizio, D., Zatzman, M., Fuligni, F., de Borja, R., Davidson, S., Edwards, M., Elvin, J. A., Hodel, K. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.048 · Cited by 765
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764 · cited 1×
“There is also uncertainty about whether to assess PD-L1 expression on tumour cells and/or immune cells.(6) Furthermore, PD-L1 expression alone is often insufficient for predicting response.”
BackgroundGuidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
Jennings, L. J., Arcila, M. E., Corless, C., Kamel-Reid, S., Lubin, I. M., Pfeifer, J., Temple-Smolkin, R. L., Voelkerding, K. V., & Nikiforova, M. N. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.01.011 · Cited by 743
High‐throughput DNA sequencing – concepts and limitations
Kircher, M., & Kelso, J. (2010) · BioEssays · doi:10.1002/bies.200900181 · Cited by 671
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Łuksza, M., Riaz, N., Makarov, V., Balachandran, V. P., Hellmann, M. D., Solovyov, A., Rizvi, N. A., Merghoub, T., Levine, A. J., Chan, T. A., et al. (2017) · Nature · doi:10.1038/nature24473 · Cited by 646
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481
Lauss, M., Donia, M., Harbst, K., Andersen, R., Mitra, S., Rosengren, F., Salim, M., Vallon-Christersson, J., Törngren, T., Kvist, A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01460-0 · Cited by 470
Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines
Roy, S., Coldren, C., Karunamurthy, A., Kip, N. S., Klee, E. W., Lincoln, S. E., Leon, A., Pullambhatla, M., Temple-Smolkin, R. L., Voelkerding, K. V., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.11.003 · Cited by 469
Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0660 · Cited by 421
Büttner, R., Gosney, J. R., Skov, B. G., Adam, J., Motoi, N., Bloom, K. J., Dietel, M., Longshore, J. W., López-Ríos, F., Penault-Llorca, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7642 · Cited by 397
Self-citationThe Makings of a Tumor Rejection Antigen
Gilboa, E. (1999) · Immunity · doi:10.1016/s1074-7613(00)80101-6 · Cited by 381
Snyder, A., Nathanson, T., Funt, S. A., Ahuja, A., Buros Novik, J., Hellmann, M. D., Chang, E., Aksoy, B. A., Al-Ahmadie, H., Yusko, E., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002309 · Cited by 341
Singh, R. R., Patel, K. P., Routbort, M. J., Reddy, N. G., Barkoh, B. A., Handal, B., Kanagal-Shamanna, R., Greaves, W. O., Medeiros, L. J., Aldape, K. D., et al. (2013) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.05.003 · Cited by 311
Sun, J. X., He, Y., Sanford, E., Montesion, M., Frampton, G. M., Vignot, S., Soria, J.-C., Ross, J. S., Miller, V. A., Stephens, P. J., et al. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005965 · Cited by 273
Chen, Y.-P., Zhang, Y., Lv, J.-W., Li, Y.-Q., Wang, Y.-Q., He, Q.-M., Yang, X.-J., Sun, Y., Mao, Y.-P., Yun, J.-P., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 232
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefebvre, C., Marabelle, A., Soria, J.-C., & Postel-Vinay, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 230
Heemskerk, B., Kvistborg, P., & Schumacher, T. N. M. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.333 · Cited by 227
Campesato, L. F., Barroso-Sousa, R., Jimenez, L., Correa, B. R., Sabbaga, J., Hoff, P. M., Reis, L. F. L., Galante, P. A. F., & Camargo, A. A. (2015) · Oncotarget · doi:10.18632/oncotarget.5950 · Cited by 226
Guidance for laboratories performing molecular pathology for cancer patients
Cree, I. A., Deans, Z., Ligtenberg, M. J. L., Normanno, N., Edsjö, A., Rouleau, E., Solé, F., Thunnissen, E., Timens, W., Schuuring, E., et al. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202404 · Cited by 214
Self-citationKhagi, Y., Goodman, A. M., Daniels, G. A., Patel, S. P., Sacco, A. G., Randall, J. M., Bazhenova, L. A., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1439 · Cited by 202
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Garofalo, A., Sholl, L., Reardon, B., Taylor-Weiner, A., Amin-Mansour, A., Miao, D., Liu, D., Oliver, N., MacConaill, L., Ducar, M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0333-9 · Cited by 179
Spigel, D. R., Schrock, A. B., Fabrizio, D., Frampton, G. M., Sun, J., He, J., Gowen, K., Johnson, M. L., Bauer, T. M., Kalemkerian, G. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9017 · Cited by 177
Current practices and guidelines for clinical next-generation sequencing oncology testing
P. Strom, S., & P. Strom, S. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0004 · Cited by 162
Lim, J., Savchenkov, A. A., Dale, E., Liang, W. G., Eliyahu, D., Ilchenko, V. S., Matsko, A. B., Maleki, L., & Wong, C. W. (2017) · RePEc: Research Papers in Economics · Cited by 152
Molecular Tumor Boards: current practice and future needs
Velden, D. L. V. D., van Herpen, C. M. L., van Laarhoven, H. W. M., Smit, E. F., Groen, H. J. M., Willems, S. M., Nederlof, P. M., Langenberg, M. H. G., Cuppen, E. P. J. G., Sleijfer, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx528 · Cited by 147
Chen, H., Luthra, R., Goswami, R. S., Singh, R. R., & Roy‐Chowdhuri, S. (2015) · Cancers · doi:10.3390/cancers7030859 · Cited by 142
Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K. F., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 140
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 122
ASBL, O. B. O. I. P., Deans, Z. C., Costa, J. L., Cree, I. A., Dequeker, E., Edsjö, A., Henderson, S. J., Hummel, M., Ligtenberg, M. J. L., Loddo, M., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2025-7 · Cited by 117
Self-citationEinaga, N., Yoshida, A., Noda, H., Suemitsu, M., Nakayama, Y., Sakurada, A., Kawaji, Y., Yamaguchi, H., Sasaki, Y., Tokino, T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176280 · Cited by 117
Koeppel, F., Blanchard, S., Jovelet, C., Génin, B., Marcaillou, C., Martin, E., Rouleau, É., Solary, É., Soria, J., André, F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188174 · Cited by 116
Special symposium: fixation and tissue processing models
Grizzle, W. E. (2009) · Biotechnic & Histochemistry · doi:10.3109/10520290903039052 · Cited by 103
Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis
Sabatini, L. M., Mathews, C., Ptak, D. M., Doshi, S., Tynan, K., Hegde, M., Burke, T. L., & Bossler, A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.010 · Cited by 100
The Challenge for Development of Valuable Immuno-oncology Biomarkers
Mehnert, J. M., Monjazeb, A. M., Beerthuijzen, J. M. T., Collyar, D. E., Rubinstein, L., & Harris, L. N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3063 · Cited by 96
Role of microsatellite instability in the management of colorectal cancers
Buecher, B., Cacheux, W., Rouleau, É., Dieumegard, B., Mitry, E., & Lièvre, A. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.10.006 · Cited by 93
Gene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 92
Hersom, M., & Jørgensen, J. T. (2017) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000460 · Cited by 91
Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
Viale, G., Trapani, D., & Curigliano, G. (2017) · BioMed Research International · doi:10.1155/2017/4719194 · Cited by 90
Pant, S., WEINER, R. S., & Marton, M. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00078 · Cited by 88
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
Voong, K. R., Feliciano, J. L., Becker, D. J., & Levy, B. P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.48 · Cited by 87
Kowanetz, M., Zou, W., Shames, D. S., Cummings, C. A., Rizvi, N. A., Spira, A. I., Frampton, G. M., Lévêque, V., Flynn, S., Mocci, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.343 · Cited by 86
The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies
Zhang, P., Lehmann, B. D., Shyr, Y., & Guo, Y. P. (2017) · International Journal of Genomics · doi:10.1155/2017/1926304 · Cited by 85
Stoy, S., Segal, J. P., Mueller, J. S., Furtado, L. V., Vokes, E. E., Patel, J. D., & Murgu, S. D. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.11.010 · Cited by 85
Al‐Kateb, H., Nguyen, T. T., Steger-May, K., & Pfeifer, J. D. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.05.004 · Cited by 84
Rozenblum, A. B., Ilouze, M., Dudnik, E., Dvir, A., Soussan‐Gutman, L., Geva, S., & Peled, N. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.021 · Cited by 84
Takamochi, K., Takahashi, F., Suehara, Y., Sato, E., Kohsaka, S., Hayashi, T., Kitano, S., Uneno, T., Kojima, S., Takeuchi, K., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.05.016 · Cited by 78
Ramalingam, S. S., Hellmann, M. D., Awad, M. M., Borghaei, H., Gainor, J. F., Brahmer, J. R., Spigel, D. R., Reck, M., O'Byrne, K. J., Paz-Ares, L. G., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct078 · Cited by 71
Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
Müller, J. N., Falk, M., Talwar, J., Neemann, N., Mariotti, E., Bertrand, M., Zacherle, T., Lakis, S., Menon, R., Gloeckner, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.014 · Cited by 58
Sato, K. A., Hachiya, T., Iwaya, T., Kume, K., Matsuo, T., Kawasaki, K., Abiko, Y., Akasaka, R., Matsumoto, T., Otsuka, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146275 · Cited by 56
Galsky, M. D., Saci, A., Szabó, P. M., Azrilevich, A., Horak, C. E., Lambert, A., Siefker-Radtke, A. O., Necchi, A., & Sharma, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx371.003 · Cited by 56
Feliubadaló, L., Tonda, R., Gausachs, M., Trotta, J.-R., Castellanos, E., López‐Doriga, A., Teulé, À., Tornero, E., Valle, J. D., Gel, B., et al. (2017) · Scientific Reports · doi:10.1038/srep37984 · Cited by 54
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer
Song, Z., Cheng, G., Xu, C., Wang, W., Shao, Y. W., & Zhang, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.004 · Cited by 45
DNA damage, tumor mutational load and their impact on immune responses against cancer
Liontos, M., Anastasiou, I. P., Bamias, A., & Dimopoulos, M. A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.11 · Cited by 43
Powles, T. B., Loriot, Y., Ravaud, A., Vogelzang, N. J., Durán, I., Retz, M. M., Giorgi, U. D., Oudard, S. M., Bamias, A., Koeppen, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.6_suppl.409 · Cited by 43
Velcheti, V., Kim, E. S., Mekhail, T. M., Dakhil, C. S. R., Stella, P. J., Shen, X., Hu, S., Paul, S. M., Shames, D. S., Yun, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12001 · Cited by 43
DiBardino, D. M., Rawson, D. W., Saqi, A., Heymann, J. J., Pagan, C. A., & Bulman, W. A. (2017) · CytoJournal · doi:10.4103/1742-6413.202602 · Cited by 36
Mehrotra, M., Singh, R. R., Loghavi, S., Duose, D. Y., Barkoh, B. A., Behrens, C., Patel, K. P., Routbort, M. J., Kopetz, S., Broaddus, R. R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21982 · Cited by 35
Grivas, P. D., Melas, M., & Papavassiliou, A. G. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.006 · Cited by 32
Comparison of tumor mutational burden (TMB) across tumor tissue and circulating tumor DNA (ctDNA).
Davis, A. A., Chae, Y. K., Agte, S., Pan, A. P., Simon, N. I., Taxter, T., Behdad, A., Carneiro, B. A., Cristofanilli, M., & Giles, F. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e23028 · Cited by 28
Moens, L., Falk-Sörqvist, E., Ljungström, V., Mattsson, J. S. M., Sundström, M., Fleur, L. L., Mathot, L., Micke, P., Nilsson, M. F., & Botling, J. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.009 · Cited by 21
Fabrizio, D. A., Malboeuf, C. M., Lieber, D. S., Zhong, S., He, J., White, E., Coyne, M. J., Silterra, J., Brennan, T., Ma, J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx363.018 · Cited by 21
Qiu, P., Pang, L., Arreaza, G., Maguire, M. G., Chang, K. C. N., Marton, M. J., & Levitan, D. J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050651 · Cited by 20
Mok, T. S. K., Gadgeel, S. M., Kim, E. S., Velcheti, V., Hu, S., Riehl, T., Schleifman, E., Paul, S. M., Mocci, S., Shames, D. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380.084 · Cited by 17
Correlation between tumor mutation burden and response to immunotherapy.
Bonta, I. R., Isac, J. F., Meiri, E., Bonta, D., & Rich, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.e14579 · Cited by 14
Weber, J. S., Horak, C. E., Hodi, F. S., Chang, H., Woods, D. M., Sanders, C. M., Robins, H. S., & Yusko, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw378.01 · Cited by 13
Singal, G., Miller, P. G., Agarwala, V., Li, G., Gossai, A., Albacker, L. A., Goldberg, M. E., He, J., Frank, S., Bourque, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.005 · Cited by 12
Szustakowski, J. D., Green, G. A., Geese, W. J., Zerba, K. E., & Chang, H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-5528 · Cited by 12
Immune response to mutant neo-antigens: Cancer's lessons for aging
Geyer, R. J., Tobet, R., Berlin, R. D., & Srivastava, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26382 · Cited by 11
Cited by
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Migden, M. R., Khushalani, N. I., Chang, A. L. S., Lewis, K. D., Schmults, C. D., Hernandez-Aya, L., Meier, F., Schadendorf, D., Guminski, A., Hauschild, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30728-4 · Cited by 496
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
Palmeri, M., Mehnert, J., Silk, A. W., Jabbour, S. K., Ganesan, S., Popli, P., Riedlinger, G., Stephenson, R., de Meritens, A. B., Leiser, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100336 · Cited by 350
Stratigos, A. J., Sekulic, A., Peris, K., Bechter, O., Prey, S., Kaatz, M., Lewis, K. D., Basset-Seguin, N., Chang, A. L. S., Dalle, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00126-1 · Cited by 286
Metadata
- Authors
- Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F.
- Venue
- ESMO Open
- Publisher
- Elsevier BV
- Published
- 2019
- Volume
- 4
- Issue
- 1
- Pages
- e000442
- ISSN
- 2059-7029 (ISSN-L)
- OpenAlex
- W2913484031
- Cited by
- 345
- References
- 111
- FWCI
- 18.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.